Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].
Molekulargewicht:
149000 (average)
Reinheit:
99.87
CAS Nummer:
[1642152-40-6]
Target-Kategorie:
Antibody-Drug Conjugates (ADCs)
Anwendungsbeschreibung:
MCE Product type: ADC Related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten